How TIRZEE Works
TIRZEE (tirzepatide) is a once-weekly injectable dual incretin receptor agonist that activates both
glucose-dependent insulinotropic polypeptide (GIP) and
glucagon-like peptide-1 (GLP-1) receptors.
By targeting two complementary incretin pathways, tirzepatide provides integrated metabolic regulation across glucose control, appetite, and energy balance.
Tirzepatide improves pancreatic hormone regulation in a glucose-dependent manner.
Drug Delivery & Administration
TIRZEE is formulated for once-weekly subcutaneous administration using a pre-filled auto-injector pen.
How does dual incretin therapy differ from GLP-1 monotherapy?
Which patient populations are most suitable for TIRZEE®?
Can TIRZEE® be used alongside other anti-diabetic therapies?
What are the key safety and tolerability considerations?
What outcomes can clinicians expect in terms of HbA1c and weight?
How does TIRZEE® impact insulin sensitivity and metabolic parameters?